Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
F 38.63 -1.00% -0.39
NTLA closed down 1.0 percent on Thursday, January 26, 2023, on 82 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Weak + Overbought Other 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
20 DMA Support Bullish -1.00%
Pocket Pivot Bullish Swing Setup -1.00%
Up 3 Days in a Row Strength -1.00%
Up 4 Days in a Row Strength -1.00%
Gapped Down Weakness -1.00%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 18 hours ago
Down 2 % about 22 hours ago
Down 1% about 23 hours ago
Rose Above Previous Day's High about 23 hours ago
Up 2% about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Intellia Therapeutics, Inc. Description

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Precision Medicine Hepatitis B Metabolism Hematopoietic Stem Cell Liver Disease Amyloid Amyloidosis Chimeric Antigen Receptor T Cell Chimeric Antigen Receptor Hepatitis B Virus Antitrypsin Deficiency CRISPR Genome Editing Cell Product Inborn Errors Of Metabolism Cas9 Transthyretin Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 104.78
52 Week Low 32.435
Average Volume 1,228,193
200-Day Moving Average 51.63
50-Day Moving Average 40.51
20-Day Moving Average 36.71
10-Day Moving Average 36.82
Average True Range 2.39
RSI 52.61
ADX 14.37
+DI 27.71
-DI 20.73
Chandelier Exit (Long, 3 ATRs) 32.95
Chandelier Exit (Short, 3 ATRs) 39.59
Upper Bollinger Bands 40.47
Lower Bollinger Band 32.95
Percent B (%b) 0.76
BandWidth 20.48
MACD Line -0.62
MACD Signal Line -1.20
MACD Histogram 0.5807
Fundamentals Value
Market Cap 2.28 Billion
Num Shares 59.1 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -19.28
Price-to-Sales 36.49
Price-to-Book 7.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 41.78
Resistance 3 (R3) 41.92 41.02 41.26
Resistance 2 (R2) 41.02 40.21 40.95 41.08
Resistance 1 (R1) 39.82 39.72 39.37 39.68 40.90
Pivot Point 38.92 38.92 38.69 38.85 38.92
Support 1 (S1) 37.72 38.11 37.27 37.58 36.36
Support 2 (S2) 36.82 37.62 36.75 36.18
Support 3 (S3) 35.62 36.82 36.01
Support 4 (S4) 35.48